DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
GDC-0810 is an investigational drug.
There have been 163 clinical trials for GDC-0810. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Leukemia. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are twelve US patents protecting this investigational drug and one hundred and two international patents.
Recent Clinical Trials for GDC-0810
|Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Horm||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the Bones||National Cancer Institute (NCI)||Phase 2|
|Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for GDC-0810
Top clinical trial sponsors for GDC-0810
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GDC-0810||Start Trial||Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer||Genentech, Inc. (South San Francisco, CA)||Start Trial|
|GDC-0810||Start Trial||Estrogen receptor mutations and uses thereof||FOUNDATION MEDICINE, INC. (Cambridge, MA)||Start Trial|
|GDC-0810||Start Trial||Estrogen receptor modulators and uses thereof||Aragon Pharmaceuticals, Inc. (San Diego, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|